Vitamin B12 Dosing for B12 Deficiency with Elevated Homocysteine and CVA
For a patient with B12 deficiency, homocysteine of 18 µmol/L, and recent CVA, initiate intramuscular vitamin B12 100 mcg daily for 6-7 days, then alternate days for 7 doses, then every 3-4 days for 2-3 weeks, followed by 100 mcg monthly for life 1.
Rationale for Intramuscular Route
The intramuscular route is mandatory in this clinical scenario for several critical reasons:
- Rapid correction is essential given the recent CVA and elevated homocysteine (18 µmol/L, which is above the treatment threshold of 14-15 µmol/L) 2
- The FDA label explicitly states to "avoid using the intravenous route" as it results in almost all vitamin being lost in urine 1
- IM administration leads to more rapid improvement and should be considered in patients with severe deficiency or severe neurologic symptoms 3
- Oral absorption is "too undependable to rely on in patients with pernicious anemia or other conditions resulting in malabsorption" 1
The CVA-Homocysteine-B12 Connection
Your patient's presentation is particularly concerning because:
- B vitamins including B12 reduce ischemic stroke by 43% in meta-analyses 2
- Metabolic B12 deficiency (which your patient has with elevated homocysteine) is present in 10.6% of stroke patients overall and 18.1% of those over 80 years 2
- Homocysteine levels in B12 deficiency (mean 23.8 µmol/L) are twice as high as controls and higher than in genetic homocystinuria 4
- After B12 administration, homocysteine decreases by 49% to normal levels 4
Specific Dosing Protocol
Initial intensive phase:
- 100 mcg IM daily × 6-7 days
- Then 100 mcg IM on alternate days × 7 doses
- Then 100 mcg IM every 3-4 days × 2-3 weeks
Maintenance phase:
- 100 mcg IM monthly for life 1
Critical Pitfalls to Avoid
Do not use oral B12 initially despite recent NICE guidance suggesting oral therapy may be adequate 5. The NICE guideline acknowledges "lack of clinical and economic evidence" and recommendations were "based on expertise of the guideline committee" rather than strong evidence. In contrast, the FDA label and stroke prevention literature provide clear evidence for IM therapy in this high-risk scenario.
Do not use cyanocobalamin if methylcobalamin or hydroxycobalamin are available - the stroke prevention guideline specifically recommends these forms over cyanocobalamin for stroke risk reduction 2.
Do not delay treatment - B12 deficiency causes "subacute combined degeneration of the spinal cord" and "prompt parenteral administration prevents progression of neurologic damage" 1.
Monitoring Response
- Recheck homocysteine after completing the intensive phase - target is <10 µmol/L for optimal stroke prevention 2
- Clinical improvement and reticulocyte response should be evident within the first week 1
- Hematologic values should normalize by 2-3 weeks 1
Why Not the 1500 mcg Dose Mentioned?
The 1500 mcg dose you referenced is not standard. The FDA-approved dosing is 100 mcg for treatment 1. Higher doses (1000 mcg) are used only for Schilling tests, not treatment 1. Excess B12 is simply excreted in urine - "50 to 98% of the injected dose may appear in the urine" within 48 hours 1.